Research Analysts Offer Predictions for MediWound Ltd.’s FY2017 Earnings (MDWD)
MediWound Ltd. (NASDAQ:MDWD) – Analysts at SunTrust Banks upped their FY2017 earnings estimates for MediWound in a report released on Tuesday. SunTrust Banks analyst B. Nudell now expects that the biopharmaceutical company will earn ($0.75) per share for the year, up from their prior forecast of ($0.80). SunTrust Banks currently has a “Buy” rating on the stock. SunTrust Banks also issued estimates for MediWound’s Q4 2017 earnings at ($0.17) EPS, FY2018 earnings at ($0.69) EPS, FY2019 earnings at ($0.44) EPS, FY2020 earnings at ($0.40) EPS and FY2021 earnings at ($0.25) EPS.
Several other equities analysts have also recently commented on the company. Oppenheimer Holdings, Inc. restated a “buy” rating and set a $10.00 target price on shares of MediWound in a research report on Monday. Jefferies Group LLC set a $10.00 target price on MediWound and gave the stock a “buy” rating in a research report on Friday, August 25th. Zacks Investment Research cut MediWound from a “hold” rating to a “sell” rating in a research report on Tuesday, August 8th. Finally, Aegis restated a “buy” rating and set a $11.00 target price on shares of MediWound in a research report on Thursday, May 25th. One equities research analyst has rated the stock with a sell rating and four have given a buy rating to the stock. MediWound currently has a consensus rating of “Buy” and a consensus target price of $9.19.
TRADEMARK VIOLATION WARNING: This news story was originally posted by American Banking News and is the property of of American Banking News. If you are viewing this news story on another website, it was copied illegally and republished in violation of US & international trademark and copyright laws. The correct version of this news story can be accessed at https://www.americanbankingnews.com/2017/09/22/research-analysts-offer-predictions-for-mediwound-ltd-s-fy2017-earnings-mdwd.html.
Shares of MediWound (NASDAQ MDWD) opened at 5.00 on Friday. The company has a 50-day moving average price of $6.30 and a 200 day moving average price of $6.53. The firm’s market capitalization is $109.77 million. MediWound has a 1-year low of $4.25 and a 1-year high of $8.58.
MediWound (NASDAQ:MDWD) last released its quarterly earnings data on Thursday, August 3rd. The biopharmaceutical company reported ($0.20) earnings per share for the quarter, missing the consensus estimate of ($0.19) by ($0.01). The business had revenue of $0.69 million during the quarter, compared to analyst estimates of $0.69 million. MediWound had a negative net margin of 752.78% and a negative return on equity of 326.32%. The business’s quarterly revenue was up 93.8% compared to the same quarter last year. During the same period last year, the business earned ($0.34) earnings per share.
Institutional investors and hedge funds have recently bought and sold shares of the company. Wells Fargo & Company MN boosted its holdings in shares of MediWound by 19.7% in the 1st quarter. Wells Fargo & Company MN now owns 53,241 shares of the biopharmaceutical company’s stock worth $351,000 after purchasing an additional 8,745 shares in the last quarter. Renaissance Technologies LLC boosted its holdings in shares of MediWound by 1.7% in the 1st quarter. Renaissance Technologies LLC now owns 75,600 shares of the biopharmaceutical company’s stock worth $499,000 after purchasing an additional 1,300 shares in the last quarter. Migdal Insurance & Financial Holdings Ltd. boosted its holdings in shares of MediWound by 20.3% in the 2nd quarter. Migdal Insurance & Financial Holdings Ltd. now owns 2,028,112 shares of the biopharmaceutical company’s stock worth $13,791,000 after purchasing an additional 342,165 shares in the last quarter. Finally, Wellington Management Group LLP boosted its holdings in shares of MediWound by 11.0% in the 1st quarter. Wellington Management Group LLP now owns 2,157,839 shares of the biopharmaceutical company’s stock worth $14,241,000 after purchasing an additional 213,745 shares in the last quarter. Hedge funds and other institutional investors own 23.47% of the company’s stock.
MediWound Ltd. is a biopharmaceutical company. The Company focuses on developing, manufacturing and commercializing therapeutics products in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders and other indications. The Company’s product, NexoBrid, is indicated for the removal of dead or damaged tissue, known as eschar, in adults with deep partial- and full-thickness thermal burns, also referred to as severe burns.
Receive News & Ratings for MediWound Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MediWound Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.